AstraZeneca Will Invest 1.3 Billion until 2027 in Catalonia

The president of AstraZeneca Spain, Rick R. Suárez, has announced that the company will invest 1.3 billion euros until 2027 in Catalonia, 500 million more than expected so far.

He said it this Thursday at the celebration of the first anniversary of AstraZeneca’s Global Hub Barcelona, ​​in which the President of the Government, Pedro Sánchez, is expected to participate through a video; the president of the Generalitat, Pere Aragonès; the mayor of Barcelona, ​​Jaume Collboni, and the Secretary of State, Juan Cruz.

Suárez has also announced the company’s desire to reach 2,000 workers at its Barcelona center in 2025 , double what had been announced and two years ahead of schedule. He recalled that next year the company center located in the Edifici Estel in Barcelona will come into operation, which he has defined as a “true meeting point for science and innovation.”

The president has assured that the company is making “a brave and firm bet” and that it is an opportunity to promote the leadership of Catalonia and the rest of Spain in the international research landscape.

Read more about teh investemnts planned by AstraZeneca in Catalonia and find the most important business news of the day with our companion app Born2Invest, available for free for both Android and iOS devices. Don’t waste your time scrolling the internet, our team of seasoned writers will do that for you, so you can stay on top of the market.

AstraZeneca: Public-private collaboration is very important

Suárez has valued public-private collaboration as a “fundamental pillar” for the company’s commitment to Spain. He explained that this investment effort “can only be carried out efficiently with the support of the institutions”, and he thanked the support he has received from the Government, the Generalitat and Barcelona City Council, which he has defined as indispensable for continue with the project.

In any case, the president of the company AstraZeneca has regretted that Spain is one of the countries in which the longest time passes between the approval of a medicine and its availability.

He has called for a “clear and equitable regulatory framework” that favors research, promotes public-private collaboration and reduces the difference with other European countries in the availability of treatments.

__

(Featured image by Joaquin Aranoa via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us